A 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of QAW039 When Added to Standard-of-care Asthma Therapy in Patients With Uncontrolled Asthma
Phase of Trial: Phase III
Latest Information Update: 24 Oct 2018
At a glance
- Drugs Fevipiprant (Primary)
- Indications Asthma
- Focus Registrational; Therapeutic Use
- Acronyms ZEAL
- Sponsors Novartis Pharmaceuticals
- 17 Oct 2018 Planned End Date changed from 11 Jun 2019 to 20 Nov 2019.
- 17 Oct 2018 Planned primary completion date changed from 11 Jun 2019 to 20 Nov 2019.
- 23 May 2018 Trial design of this and another study (NCT03226392) presented at the 114th International Conference of the American Thoracic Society